Bsense Bio Therapeutics ⚠ Under review

About

Headcount over time

Offices

Q&A

What is Bsense Bio Therapeutics' primary focus?

Bsense Bio Therapeutics is developing small molecules biotechnology designed to treat sensory hyperexcitability-related disorders.

When was Bsense Bio Therapeutics founded?

Bsense Bio Therapeutics was founded in September 2018.

How many employees does Bsense Bio Therapeutics currently have?

Bsense Bio Therapeutics has 1-10 employees.

What is Bsense Bio Therapeutics' total funding to date?

Bsense Bio Therapeutics has raised a total of $2,700,000 USD.

When did Bsense Bio Therapeutics raise its Seed round?

Bsense Bio Therapeutics raised a Seed round in September 2018, securing $2,700,000 USD.

What is the company's approach to treating sensory hyperexcitability-related disorders?

Bsense Bio Therapeutics is pioneering a novel approach targeting multiple hyperexcitability-related mechanisms using a single compound, specifically targeting two cation channels, TRPV1 and Kv7.2/3.

What is the current product stage of Bsense Bio Therapeutics?

Bsense Bio Therapeutics is currently in the R&D product stage.

What is the primary sector of Bsense Bio Therapeutics?

The primary sector of Bsense Bio Therapeutics is Health Tech & Life Sciences.

Team · 8

Asher Peretz

Founder · Co-founder

Prof. Bernard Attali

Founder · Inventor of the technology, Consultant

Silvia Noiman

Executive Chairperson

Haim Belinson

Chief Scientific Officer

Dr. Pelled

Senior Biopharmaceutical Executive

Shmuel Tuvia

Chief Development Officer

Dr. Raveh

VP Research

Mr. Breski

BOD Member

Sectors & technology

Highlights

Tags